BACK

Gastric > Gastric/GEJ cancer

Clinical trial information


Select trial for more information

Area under investigation,Gastric cancer,Gastric/GEJ cancer=true

ARTEMIDE-Gastric01 trial overview

Tumor

HER2+ locally advanced or metastatic gastric or GEJ cancer whose tumors express PD-L1 CPS ≥1

Trial Identifier

NCT06764875

Phase

III

Stage

Untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma

Regimen

T-DXd + rilvegostomig + fluoropyrimidine vs. trastuzumab + chemotherapy + pembrolizumab vs. trastuzumab + chemotherapy + rilvegostomig

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

CLARITY-Gastric01 trial overview

Tumor

Advanced or metastatic gastric or GEJ adenocarcinoma expressing Claudin18.2, ≥2L

Trial Identifier

NCT06346392

Phase

III

Regimen

Sonesitatug vedotin (different doses); investigator's choice of chemotherapy

Visit ct.gov
Go

CLARITY-Gastric02 trial overview

Tumor

1L advanced or metastatic GC, GEJ or esophageal adenocarcinoma expressing Claudin18.2

Trial Identifier

NCT07431281

Phase

III

Stage

1L advanced or metastatic GC, GEJ or esophageal adenocarcinoma expressing Claudin18.2

Regimen

Cohort 1: sonesitatug vedotin + rilvegostomig + capecitabine; sonesitatug vedotin + nivolumab + capecitabine; nivolumab + CAPOX or FOLFOX. Cohort 2: Sonesitatug vedotin + capecitabine; CAPOX or FOLFOX ± zolbetuximab

Visit ct.gov
Go

CLARITY-PanTumor01 trial overview

Tumor

Claudin 18.2-positive advanced solid tumors (gastric/GEJ cancer, pancreatic adenocarcinoma, BTCs)

Trial Identifier

NCT06219941

Phase

II

Regimen

Sonesitatug vedotin; sonesitatug vedotin + chemotherapy

Visit ct.gov
Go

DESTINY-Gastric03 trial overview

Tumor

HER2-expressing advanced/metastatic gastric/GEJ and esophageal adenocarcinoma

Trial Identifier

NCT04379596

Phase

Ib/II

Stage

Advanced

Regimen

T-DXd ± (chemotherapy or durvalumab or pembrolizumab); T-DXd + chemotherapy + (durvalumab or pembrolizumab); T-DXd + volrustomig + chemotherapy; T-DXd + rilvegostomig + chemotherapy

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

DESTINY-Gastric04 trial overview

Tumor

HER2+ unresectable and/or metastatic gastric or GEJ adenocarcinoma

Trial Identifier

NCT04704934

Phase

III

Stage

Advanced

Regimen

T-DXd; ramucirumab + paclitaxel

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.

Go

DESTINY-Gastric05 trial overview

Tumor

Unresectable, locally advanced or metastatic HER2+ gastric/GEJ cancer

Trial Identifier

NCT06731478

Phase

III

Stage

Untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma

Regimen

T-DXd + chemotherapy ± pembrolizumab vs trastuzumab + chemotherapy ± pembrolizumab

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.

Go

GEMINI-GC trial overview

Tumor

Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Trial Identifier

NCT05702229

Phase

II

Regimen

Volrustomig + (XELOX or FOLFOX); rilvegostomig + (XELOX or FOLFOX); volrustomig + sonesitatug vedotin + (5-FU or capecitabine); sonesitatug vedotin + 5-FU or capecitabine ± rilvegostomig

Visit ct.gov
Go

GEMINI-PeriOp Gastric trial overview

Tumor

Locally advanced resectable GEJ adenocarcinoma

Trial Identifier

NCT07069712

Phase

II

Stage

Locally advanced resectable gastric, GEJ, or esophageal adenocarcinoma

Regimen

Sonesitatug vedotin + rilvegostomig and 5-FU or capecitabine; T-DXd + rilvegostomig and 5-FU or capecitabine; rilvegostomig + FLOT chemotherapy

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.

Go

PETRA trial overview

Tumor

Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)

Trial Identifier

NCT04644068

Phase

I/IIa

Regimen

Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

TROPION-PanTumor03 trial overview

Tumor

Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)

Trial Identifier

NCT05489211

Phase

II

Regimen

Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin

Visit ct.gov
Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.